In this conversation, updated MASLD CPG co-authors Frank Tacke and Elisabetta Bugianesi discuss some of the guidelines’ key goals and issues surrounding the screening, diagnosis and management of MASLD patients.
In this conversation, updated MASLD CPG co-authors Frank Tacke and Elisabetta Bugianesi explain how the guidelines process benefitted from the close collaboration between EASL, EASD, and EASO.
Two of the co-authors of the upgraded MASLD Clinical Practice Guidelines (CPG), Elisabetta Bugianesi and Frank Tacke join Louise Campbell and Roger Green to discuss the guidelines.
Co-authors Elisabetta Bugianesi and Frank Tacke join Louise Campbell and Roger Green to discuss the new MASLD Clinical Practice Guidelines from EASL, EASDand EASO.
In this conversation from EASL Congress 2023, Stephen Harrison, Jörn Schattenberg and Roger Green discuss the future roles of FGF-21s and incretin agonists in what was then known as NASH and NAFLD therapy.
This conversation covers some of the other major drug development stories from the EASL Congress 2024, with special focus on denifenstat, ION-224 and TAK-227, plus a look at the SPECIAL study on bariatric surgery and cirrhosis.
This conversation focuses on the role FGF-21s will play in long-term advanced fibrosis treatment: induction or long-term therapy?
This conversation explores issues regarding incretin agonists and discusses results from the efruxiermin late-breaker at the EASL Congress 2024.
Naim Alkhouri and Mazen Noureddin join co-hosts Jörn Schattenberg and Roger Green to discuss the major drug development stories from the EASL Congress 2024.
As the conversation wraps up, Jörn Schattenberg and Michelle Long discusses abstracts they will present at EASL Congress 2024, with Jörn focusing on new MASLD drug development and Michelle on an aggregation of studies sponsored by Novo Nordisk.
